The malignant psoas syndrome (MPS) is a rare and challenging cancer pain state that is often refractory to rational polymodal analgesic therapy. We describe the first case of cervix cancer-related MPS due to extrinsic psoas muscle infiltration and review the therapeutic trajectory and outcome. The anatomic determinants, pain mechanisms, and current and proposed novel treatment strategies for MPS are discussed.
Get full access to this article
View all access options for this article.
References
1.
StevensMJ, GonetYM. Malignant psoas syndrome: Recognition of an oncologic entity. Australas Radiol, 1990; 34:150–154.
AgarM, BroadbentA, ChyeR. The management of malignant psoas syndrome: Case reports and literature review. J Pain Symptom Manage, 2004; 28:282–293.
4.
DasS, JebaJ, GeorgeR. Cancer and treatment related pains in patients with cervical carcinoma. Indian J Palliative Care, 2005; 11:74–81.
5.
CalavaJM, PattRB, ReddyS, VarmaDG, ChiangJ. Psoas sheath chemical neurolysis for management of intractable leg pain from metastatic liposarcoma. Clin J Pain, 1996; 12:69–75.
6.
DouglasI, BushD. The use of patient-controlled boluses of local anaesthetic via a psoas sheath catheter in the management of malignant pain. Pain, 1999; 82:105–107.
SimIW, WebbT. Anatomy and anaesthesia of the lumbar somatic plesxus. Anaesth Intensive Care, 2004; 32:178–187.
10.
RofstadEK, SundforK, LyngH, TropeCG. Hypoxia-induced treatment failure in advanced squamous cell cancer of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer, 2000; 83:354–359.
11.
MoriwakiK, YugeO, TanakaH, SasakiH, IzumiH, KanekoK. Neuropathic pain and prolonged regional inflammation as two distinct symptomatological components in CPRS with patchy osteoporosis: A pilot study. Pain, 1997; 72:277–282.
12.
SchiableHG. Basic mechanisms of deep somatic pain. McMahonSB, KoltzenburgM. Wall and Melzack's Textbook of Pain, 5th. Philadelphia: Elsevier Churchill Livingstone, 2006; 621–633.
13.
VierckCJ. Mechanisms underlying development of spatially distributed chronic pain (fibromyalgia)Pain, 2006; 124:242–263.
14.
MenseS, StahnkeM. Response in muscle afferent fibres of slow conduction velocity to contractions and ischaemia in the cat. J Physiol, 1983; 342:383–394.
15.
FuK-Y, LightAR, MaixnerW. Long lasting inflammation and long term hyperalgeasia after subcutaneous formalin injection into rat hindpaw. J Pain, 2001; 2:2–11.
16.
LynnB. Efferent function of nociceptors. BelmonteC, CerveroF. Neurobiology of Nociceptors. Oxford: Oxford University Press, 1996.
17.
StaudR, VierckC, RobinsonM, PriceD. Spatial summation of heat pain within and across dermatomes in fibromyalgia patients and pain free subjects. Pain, 2004; 111:342–350.
18.
WoolfCJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: Implications for diagnosis and therapy. Life Sci, 2004; 74:2605–2610.
19.
HöslK, ReinoldH, HarveyRJ, MüllerU, NarumiyaS, ZeilhoferHU. Spinal prostaglandin E receptors of the EP2 subtype and the glycine receptor α3 subunit which mediate central inflammatory hyperalgesia do not contribute to pain after peripheral nerve injury or formalin injection. Pain, 2006; 126:46–53.
20.
BenedettiC, BrockC, CleelandC, CoyleN, DubéJE, FerrellB, HassenbuschS3rd, JanjanNA, LemaMJ, LevyMH, LoscalzoMJ, LynchM, MuirC, OakesL, O'NeillA, PayneR, SyrjalaKL, UrbaS. Weinstein SM; National Comprehensive Cancer Network: NCCN Practice Guidelines for Cancer Pain. Oncology (Williston Park), 2000; 14:135–150.
21.
QuigleyC. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev, 2004; 3:CD004847.
KhoromiS, CuiL, NackersL, MaxMB. Morphine, nortriptyline and their combination vs placebo in patients with chronic lumbar root pain. Pain, 2007; 130:66–75.
24.
KoppertW, WehrfritzA, KorberN, SittlR, AlbrechtS, SchüttlerJ, SchmelzM. The COX isoenzyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain, 2004; 108:148–153.
25.
World Health Organization. Cancer Pain Relief, 2nd. Geneva: World Health Oorganization, 1996.
26.
DavisMP, WalshD, LagmanR, LeGrandSB. Controversies in pharmacotherapy of pain management. Lancet Oncol, 2005; 6:696–704.
27.
SmithTJ, StaatsPS, DeerT, StearnsLJ, RauckRL, Boortz-MarxRL, BuchserE, CatalàE, BryceDA, CoynePJ, PoolGE. Implantable Drug Delivery Systems Study Group: Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: Impact on pain, drug-related toxicity, and survival. J Clin Oncol, 2002; 20:4040–4049.
TaskerRR, DeCarvalhoGTC, DolanEJ. Intractable pain of spinal origin: Clinical features and implications for surgery. J Neurosurg, 1992; 77:373–378.
30.
HasselaarJGJ, VerhagenSC, VissersKCP. When cancer symptoms cannot be controlled: The role of palliative sedation. Curr Opin Supp Palliat Care, 2009; 3:14–23.
31.
Marre-BrunenghiG, CamorianoR, ValleM, BoeroS. The psoas muscle as a cause of low back pain in infantile cerebral palsy. J Orthop Traumatol, 2008; 9:43–47.
